All the news Showing 10 of 51 articles from: NAFLDGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources NAFLD a rising cause of liver disease in people with HIV Liz Highleyman / 23 April 2019 Now that hepatitis C can be successfully treated, non-alcoholic fatty liver disease (NAFLD) is becoming an increasingly important cause of serious liver problems and liver-related death among people living with HIV in the ... Obeticholic acid improves liver fibrosis in people with NASH Liz Highleyman / 12 April 2019 Obeticholic acid (Ocaliva) led to a significant improvement in liver fibrosis related to non-alcoholic steatohepatitis (NASH), offering a potential future option for an increasingly common liver disease with no good current therapies, researchers ... Experimental therapy improves liver health in people with fatty liver disease Liz Highleyman / 31 January 2019 NGM282, an experimental fibroblast growth factor analogue, reduced liver fat build-up and the development of scar tissue in people with non-alcoholic steatohepatitis, according to studies presented at the recent AASLD Liver Meeting in ... Aramchol reduces liver fat in people with NASH Liz Highleyman / 02 January 2019 A novel type of experimental therapy led to a significant reduction in liver fat and improvement in liver health among people with non-alcoholic steatohepatitis (NASH), according to study presented at the recent AASLD Liver ... Lean people can develop fatty liver disease Liz Highleyman / 17 December 2018 Metabolically healthy lean people may develop non-alcoholic fatty liver disease (NAFLD), although this is much more common among people with obesity and metabolic abnormalities, according to research presented at the AASLD Liver ... Burden of severe liver disease due to fatty liver will more than double by 2030 Keith Alcorn / 07 December 2018 If current trends in obesity and diabetes continue, at least 520 million people will be living with non-alcoholic fatty liver disease (NAFLD) in western Europe, China, Japan and the United States by ... Thyroid hormone receptor agonists reduce liver fat in people with NAFLD Liz Highleyman / 29 November 2018 Thyroid hormone activation appears to be a promising approach for treating fatty liver disease, according to a pair of studies presented at the AASLD Liver Meeting this month in San Francisco. Two thyroid ... People with fatty liver disease are at greater risk for multiple cancers Liz Highleyman / 12 November 2018 People with non-alcoholic fatty liver disease (NAFLD) were found to have higher rates of cancer, with the greatest increase observed for gastrointestinal cancers, according to findings presented yesterday at the 2018 AASLD Liver ... HIV infection is a risk factor for liver fat accumulation Liz Highleyman / 13 August 2018 People living with HIV are about twice as likely to develop steatosis, or fat accumulation in the liver, even if they don't have hepatitis B or C co-infection, according to a study presented at ... Mixed results for experimental therapies for NASH Liz Highleyman / 22 June 2018 The recent International Liver Congress in Paris featured several presentations on investigational therapies for fatty liver disease. Drugs with a range of different mechanisms – including the thyroid hormone receptor agonist MGL-3196, ... ← Prev1...23456Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD NASH Experimental treatments for NASH/NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive